Ke Ding

发表

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

Su Qiu, Guoping Wang, Wei Gao, 2006, Journal of medicinal chemistry.

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Dajun Yang, Su Qiu, Guoping Wang, 2008, Proceedings of the National Academy of Sciences.

Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins.

Shaomeng Wang, Renxiao Wang, Chao-yie Yang, 2007, Journal of medicinal chemistry.

Structure-based design of potent non-peptide MDM2 inhibitors.

J. Deschamps, Shaomeng Wang, Yipin Lu, 2005, Journal of the American Chemical Society.

An efficient synthesis of optically pure (S)-2-functionalized 1,2,3,4-tetrahydroquinoline

J. Deschamps, J. Flippen-Anderson, Shaomeng Wang, 2004 .

Synthesis of spirooxindoles via asymmetric 1,3-dipolar cycloaddition

J. Deschamps, Shaomeng Wang, Ke Ding, 2005 .

Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

Shanghai Yu, Dajun Yang, Su Qiu, 2009, Journal of medicinal chemistry.

A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy

Shaomeng Wang, Yi Sun, Ke Ding, 2008, Cancer biology & therapy.

Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.

Shaomeng Wang, Ke Ding, Jianyong Chen, 2005, Bioorganic & medicinal chemistry letters.

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Shaomeng Wang, Yipin Lu, T. Carey, 2008, Molecular Cancer Therapeutics.

Efficient synthesis of isoflavone analogues via a Suzuki coupling reaction

Shaomeng Wang, Ke Ding, 2005 .

Efficient Synthesis of Isoflavone Analogues via a Suzuki Coupling Reaction.

Shaomeng Wang, Ke Ding, 2005 .

Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands.

J. Deschamps, Shaomeng Wang, Yipin Lu, 2005, Journal of medicinal chemistry.

Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility.

Shaomeng Wang, Ke Ding, Jianyong Chen, 2006, Bioorganic & medicinal chemistry letters.

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53

Dajun Yang, Ke Ding, S. Wang, 2009, British Journal of Cancer.